Billiontoone (NASDAQ:BLLN) Stock Price Down 6.3% - Here's Why

Key Points

• Shares fell 6.3% intraday to about $86.18 after trading as low as $88.67, with volume roughly 60,310 shares (down ~78% from the daily average).
• Analysts have trimmed price targets (e.g., BTIG to $140, Guggenheim to $100, JPMorgan to $145) but the consensus remains a Moderate Buy with a $126.71 average target (6 Buy, 3 Hold, 1 Sell).
• BillionToOne reported an EPS and revenue beat (EPS $0.11 vs $0.04; revenue $96.05M, +113% YoY), yet it trades at a high PE (~407.8) with a $3.94B market cap while several institutional investors have recently added stakes.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) shares were down 6.3% during mid-day trading on Thursday . The stock traded as low as $88.67 and last traded at $86.1820. Approximately 60,310 shares changed hands during trading, a decline of 78% from the average daily volume of 279,035 shares. The stock had previously closed at $91.98.

Analyst Ratings Changes

Several equities analysts have issued reports on BLLN shares. BTIG Research lowered their target price on shares of Billiontoone from $160.00 to $140.00 and set a "buy" rating on the stock in a research note on Thursday, March 5th. Guggenheim lowered their target price on shares of Billiontoone from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. JPMorgan Chase & Co. reduced their price target on shares of Billiontoone from $150.00 to $145.00 and set an "overweight" rating for the company in a research report on Wednesday, December 10th. Weiss Ratings began coverage on shares of Billiontoone in a research report on Tuesday, February 3rd. They set a "sell (d)" rating for the company. Finally, Wall Street Zen raised shares of Billiontoone from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $126.71.

Billiontoone Stock Performance

The firm has a market capitalization of $3.94 billion and a PE ratio of 407.77. The company has a current ratio of 11.69, a quick ratio of 11.32 and a debt-to-equity ratio of 0.12. The company's 50-day moving average price is $79.34.

Billiontoone (NASDAQ:BLLN - Get Free Report) last released its quarterly earnings results on Wednesday, March 4th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.04 by $0.07. The business had revenue of $96.05 million for the quarter, compared to analysts' expectations of $85.85 million. The firm's quarterly revenue was up 113.0% on a year-over-year basis.

Institutional Investors Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new stake in Billiontoone in the 4th quarter worth approximately $230,000. T. Rowe Price Investment Management Inc. purchased a new stake in Billiontoone in the 4th quarter worth approximately $8,277,000. Invesco Ltd. purchased a new stake in Billiontoone in the 4th quarter worth approximately $15,535,000. XTX Topco Ltd purchased a new stake in Billiontoone in the 4th quarter worth approximately $1,692,000. Finally, Quadrature Capital Ltd purchased a new stake in Billiontoone in the 4th quarter worth approximately $614,000.

Billiontoone Company Profile

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.